SCHEMBL9648939

SCHEMBL9648939

OOc1c(Cl)ccc2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.54
CYP1A2 P05177 3/20 0.46
ALDH1A1 P00352 2/20 0.44
HSD17B10 Q99714 2/20 0.44
TSHR P16473 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
HPRT1 P00492 1/20 0.41
PTPN22 Q9Y2R2 1/20 0.39
PAX8 Q06710 1/20 0.39
KCNH2 Q12809 1/20 0.38
HIF1A Q16665 1/20 0.38
CYP1B1 Q16678 1/20 0.38
KMT2A Q03164 1/20 0.37
ATM Q13315 1/20 0.37
MAPT P10636 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LMNA P02545 2/20 0.37
NCEH1 Q6PIU2 1/20 0.37
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10938638 0.83 CYP2A6 (0.58) CYP2A6CYP1A2ALDH1A1HSD17B10TSHR
SCHEMBL31005180 0.79 CYP2A6 (0.48) CYP2A6CYP1A2ALDH1A1HSD17B10TSHR
SCHEMBL269051 0.79 CYP2A6 (0.48) CYP2A6CYP1A2ALDH1A1HSD17B10TSHR
SCHEMBL8153278 0.77 CYP2A6 (0.47) CYP2A6CYP1A2ALDH1A1HSD17B10TSHR
SCHEMBL10438032 0.77 ALDH1A1 (0.46) CYP2A6CYP1A2ALDH1A1HSD17B10TSHR
SCHEMBL25273082 0.76 CYP2A6 (0.46) CYP2A6CYP1A2ALDH1A1HSD17B10TSHR
SCHEMBL5852315 0.76 CYP2A6 (0.46) CYP2A6CYP1A2ALDH1A1HSD17B10TSHR
SCHEMBL7108615 0.75 CYP2A6 (0.48) CYP2A6CYP1A2ALDH1A1HSD17B10TSHR
SCHEMBL7011793 0.75 CYP2A6 (0.48) CYP2A6CYP1A2ALDH1A1HSD17B10TSHR
SCHEMBL25385558 0.75 CYP2A6 (0.48) CYP2A6CYP1A2ALDH1A1HSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5118611-A Useful for diagnostic, imaging treatment of cancer involving antibody binding interaction with marker ADEZA BIOMEDICAL CORPORATION (US) 1992-06-02 US disclosed
EP-0352722-A2 Adenocarcinoma antigen binding methods and reagents Smith, Lloyd H. (US) 1990-01-31 EP disclosed